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Abstract NF-κB regulates several important expressions,
such as cytokine release, anti-apoptosis, adhesion molecule
expression, and cell cycle processing. Several NF-κB
inhibitors have been discovered as an anti-tumor or anti-
inflammatory drug. The activity of NF-κB transcription
factor is negatively regulated by IκB binding. In this study,
IκB assay system was established and IκB–EGFP fusion
protein was used as an indicator to monitor the effects of
substances on the IκB degradation. The results indicated that
the chosen hydroquinone could inhibit the IκB degradation
and cause the cell de-attachment from the bottom of culture
plate. In addition, this system could also monitor the IκB
degradation of microbial metabolite of natural mixtures of
propolis. Thus, the IκB assay system may be a good system
for drug discovery related to microbial metabolite.
Keywords Microbial metabolite.Antioxidant.IκB.
EGFP.Hydroquinone.Propolis
1 Introduction
NF-κB is an inducible transcription factor involved in the
regulation of gene expression for cytokine release, anti-
apoptosis, adhesion molecule, and cell cycle regulation [1].
There are five members in the NF-κB family composed of
p50/p105, p52/p100, c-Rel, Rel A, and Rel B [2]. These
components all have a consensus amino acid domain that is
Rel homology domain (RHD). RHD, a regulatory element
for activity of NF-κB, is involved in NF-κB dimerization
and IκB binding. Without intracellular stimulation, IκB
associates with RHD of NF-κB to inhibit NF-κBm i g r a t i o n
into the nucleus and retain NF-κB in cytosol. As extracellular
signals of NF-κB activation transduce into cells, IκB will be
phosphorylated and results indegradation. The degradation of
IκB can abolish the inhibitory effect on the activity of NF-κB.
Therefore, the amount of intracellular IκB can be an indicator
for the activity of NF-κB.
The microbial metabolite is an important source of
certain medical reagents. Particularly, many investigators
indicated that microbial metabolites provide a source of
abundant antioxidants. Previous investigations revealed that
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[3–5]. Antioxidants, such as β-catenin and bortezomib,
have been reported to have a cytotoxic ability against tumor
cells by inhibiting the activity of NF-κB[ 6, 7]. Therefore,
utilizing the principle of NF-κB activity regulation to
develop a drug discovery system may help to rapidly find
new drugs.
In this study, we have focused on the establishment of
a rapid and precise screening system with NF-κB
inhibitory activity, and the metabolite products of
microbes and the natural extract propolis were tested in
this system. The plasmid pIκB–EGFP, which contained a
chimeric gene that encodes a fusion protein, green
fluorescent protein (EGFP) fused with IκB-α (IκB–
EGFP), was used to establish the screening system. The
pIκB–EGFP was transfected into cells and the trans-
fected cells were treated with microbe-derived antiox-
idants or propolis, and then the fluorescence intensities
of IκB–EGFP in the transfected cells were determined by
flow cytometry. In our system, if the drug candidates
have the activity against IκB degradation, they would
protect the IκB–EGFP from degradation and would result
in an increase in fluorescence level in the transfected
cells. Therefore, the IκB–EGFP proteins were used as an
indicator for the degree of IκB degradation to reflect the
level of NF-κB activation in the cell. In the screening
program, we found that the pure chemical microbe-
derived hydroquinone (HQ) and certain propolis obtained
from Brazil have significant activities against IκB
degradation. Furthermore, HQ was studied and showed
that it could affect cell adhesion activity and that the
feature is exactly associated with NF-κB activity except
for its anti-IκB degradation activity. In conclusion, this
study showed that the drug discovery system can exactly
identify the effective substance with anti-IκB degradation
ability no matter whether the effective substance exists as
a pure chemical compound or as a natural mixture. Our
data reveals that the transgenic cells can be a convenient,
efficient, and exact tool to rapidly identify a new drug
for improvement of human health.
2 Materials and Methods
2.1 Reagents
Plasmid pIκB–EGFP was purchased from BD Biosciences
Clontech (CA, USA). Rabbit anti-human IκB-α and rabbit
anti-phosphorylated IκB-α polyclonal IgGs were purchased
from Calbiochem-Novabiochem Corporation (CA, USA).
Hydroquinone (HQ), homogentisic acid (HA), protocatechuic
acid(PA),andβ-phenylpyruvicacid(β-PPA)werepreviously
isolated from fermentation broth of Streptomyces sp. in our
laboratory as an antioxidant. The antioxidant curcumin is a
well-known inhibitor for IκB degradation and was purchased
from Sigma Corporation (St Louis, MO, USA).
2.2 Cell Lines and Cell Culture
TheK-BALB(murinesarcomavirus-transformedBALB/3T3),
293 (human fetus kidney cells), Hep3B (human hepatocellular
carcinoma), Daudi (human Burkitt’s lymphoma), and
COLO320 (human colorectal adenocarcinoma) were
kindly provided by Dr. Steve R. Roffler, Academia
Sinica, Taipei, Taiwan. K-BALB, 293, and Hep3B were
grown in Dulbecco’s modified Eagle’sm e d i u m( D M E M )
supplemented with 10% fetal bovine serum (FBS),
penicillin (100 U/ml), and streptomycin (100 U/ml)
(DMEM complete media) at 37°C in a humidified 5%
CO2 atmosphere. Daudi and COLO320 cells were prop-
agated in RPMI 1640 medium with 2 mM L-glutamine
adjustedtocontain1.5g/lsodiumbicarbonate,4.5g/lglucose,
10 mM HEPES, 1 mM sodium pyruvate, 10% FBS, penicillin
(100 U/ml), and streptomycin (100 U/ml). Huh7 cell line was
kindly provided by Dr. Chao-Lin Huang, Institute of
Preventive Medicine, Taipei, Taiwan, and was grown in
DMEM supplemented with 10% FBS, penicillin (100 U/ml),
and streptomycin (100 U/ml).
2.3 Transgene Expression and Microbial
Metabolite-Derived Antioxidant Activity Measurement
Before transfection, 2.5×10
5 Huh7 or 293 cells per well
were cultured overnight in six-well plates. Cells were
typically ∼70% confluent at the time of the experiment. In
all transfection assays, 200 μl/well of the transfection
sample containing 3 μg plasmid DNA (pIκB–EGFP) and
10 μl Lipofectamine (Invitrogen, NY, USA) in Opti-MEM
(Invitrogen) were added and incubated with the cells. The
2 ml/well serum containing DMEM complete media was
added after 16 h, and gene-transfected cells were re-
suspended and divided equally into each well of a 24-well
plate. The 24-h incubation was then performed and 100 μM
of each antioxidant, HQ, HA, PA, and β-PPA was
administered for 24 h on the transfectants. Next, 50 ng/ml
of phorbol 12-myristate 13-acetate (PMA) (Sigma) was
added after 2-h incubation to induce IκB–EGFP degrada-
tion. IκB–EGFP reporter gene expression was assayed with
flow cytometry (BD Biosciences Clontech). Assays were
performed in triplicate.
2.4 Propolis Preparation and Application
into the IκB–EGFP Drug Discovery System
Taiwan propolis (propolis 1 and 2), Brazil red propolis
(propolis 3 and 4), and Brazil green propolis (propolis 5
132 Lin et al.and 6) were provided by Dr. Rea-Min Chu’s laboratory and
dissolved in 80% ethanol. Then 2.5×10
5 of 293 cells per
well were transfected with 3 μgp I κB–EGFP. After
24-h incubation, 1 g/ml of different propolis sources
described above, ethanol (80%), and curcumin (10 μM)
were added into transfected cells. After 2-h incubation,
pIκB–EGFP-transfected 293 cells were treated with 50 ng/ml
PMA to initiate IκB–EGFP degradation. Curcumin was
used as positive control for its ability to inhibit IκB
decomposition. IκB–EGFP reporter gene expression was
assayed by flow cytometry after 24-h incubation of
propolis.
2.5 Western Blot for IκB Expression
After HQ treatment (0–100 μM) for 48 h, pIκB–EGFP-
transfected 293 cells were harvested. For immunoblotting,
equivalent amounts of cell lysate were resolved by SDS–
PAGE (10%) and transferred onto PVDF membranes.
After blocking, the membranes were incubated with the
anti-IκB and anti-phosphorylated IκB antibody (Santa
Cruz Biotech, Heidelberg, Germany). The membranes
were then treated with goat anti-rabbit peroxidase-
conjugated antibody, and the immunoreactive proteins
were detected using enhanced chemiluminescence kits
(Pierce, Rockford, IL, USA) according to the manufacturer’s
instructions.
2.6 293 Cells Detachment Assay
293 Cells (2.5×10
5/well) were seeded in a six-well plate
and cultured overnight at 37°C in a humidified 5% CO2
atmosphere. After overnight incubation, low dosage of HQ
(10 μM) was added into each well and the cell growth
pattern was observed (0–4 h).
2.7 Cell Cytotoxicity Assay
HQ cytotoxicity against COLO320, Daudi, K-BALB, and
Hep3B cell lines was determined via MTS assay (CellTiter
96® AQueous One Solution Cell Proliferation Assay;
Promega, WI, USA). For each cell line tested, a 96-well
microtiter plate was prepared by adding 100 μlo fc e l l s
suspended in growth medium at a concentration of
2×10
5 cells/100 μl/well to each experimental and control
well. One hundred microliters of growth medium contain-
ing different concentrations of HQ was added to the
experimental wells. Another growth medium (200 μl) was
addedtoonecolumntoserveasablank.After48-hincubation
at 37°C under a water-saturated sterile atmosphere with 5%
CO2, the medium was removed, and then fresh growth
medium (100 μl) and MTS (20 μl/well) were applied to each
well for a 4-h incubation. The absorbance of each well at
450 nm was determined by analysis with an ELISA reader
(TECAN, Austria). LD50 was defined as the dosage of HQ
that produces death in 50% (calculated from the absorbance)
of the exposed cell population.
3 Results
3.1 Antioxidants Derived from Microbial Metabolites
were Selected for Anti-IκB Degradation Activity
with the IκB–EGFP Drug Discovery System
The pIκB–EGFP plasmid was transfected into Huh 7 cells,
and the genetically modified cells were used as an indicator
to disclose the candidates with the activity against IκB
degradation as NF-κB inhibitors. These antioxidants, such
as HQ, PA, β-PPA, and HA, were further determined
whether they had anti-IκB degradation activities. The
genetically modified cells were incubated with the
microbe-derived antioxidants (100 μM), and later PMA
(50 ng/ml) was added to accelerate the process of IκB
degradation. After incubation, the fluorescence intensities
of the genetically modified Huh 7 cells were determined by
flow cytometry. The results showed that the addition of HQ
caused accumulated IκB–EGFP proteins in the cytoplasm of
the transfectant cells to result in 3-fold higher fluorescence
intensities compared with the untreated transfected cells,
whereasthe otherscouldnotaffectthe fluorescenceintensities
(Fig. 1). Therefore, HQ may have the activity to inhibit the
IκB degradation.
AlthoughwefoundthatthefluorescenceintensityofpIκB–
EGFP transfectant cells is increased after the addition of HQ,
many chemicals can be induced to emit fluorescence by the
laser beam of a flow cytometer. Therefore, HQ was
determined whether the fluorescence was due to spontaneous
fluorescence emission of HQ addition or IκB–EGFP protein
accumulation. The results showed that mock-transfected Huh
7 cells treated with 20 μMo r1 0 0μM HQ had the same
fluorescence as untreated cells (Fig. 2). The fluorescence
intensity of the transfected cells treated with 20 and 100 μM
HQ was higher than that of the untreated transfected cells.
These results indicated that the change in fluorescence was
due to IκB–EGFP protein accumulation but not spontaneous
fluorescence of HQ.
Because the transfection efficiency of Huh 7 cells by
liposome method is not high enough, we chose 293 cells to
replace Huh 7 cells. Figure 3 shows that 293 transfected
cells had higher EGFP fluorescence increase (about 7.3-
fold), compared with untransfected 293 cells (Fig. 3,
columns 1 and 2), than the change in Huh 7 cells (3.2-
fold; Fig. 2, columns 1 and 4). The difference in
fluorescence intensity between Huh 7 and 293 transfectant
was due to the variation of transfection efficiency. The
Microbial Metabolites with NF-κB Inhibitor Activity 133pCMV–EGFP plasmid that can constantly express EGFP
proteins in cytoplasm has been used to determine the
transfection efficiency. The study revealed that the trans-
fection efficiency for Huh 7 and 293 cells was about 25%
and 65% (results not shown). TNF-α has been reported as
an activator for NF-κB. Therefore, TNF-α shall enhance
degradation of IκB–EGFP to result in a decrease in
fluorescence. The results showed that TNF-α does decrease
the fluorescence of pIκB–EGFP-transfected 293 cells.
However, previous treatment of HQ can increase the
fluorescence of pIκB–EGFP-transfected 293 cells even in
the presence of TNF-α (Fig. 3). Therefore, HQ can inhibit
the degradation of IκB in 293 cells as well as in Huh 7
cells.
3.2 The Activities of Anti-IκB Degradation of the Natural
Extracts are Detectable by the IκB–EGFP Drug Discovery
System
The extracts of propolis were used as samples to verify
whether the IκB–EGFP drug discovery system can be
responsible for the substances that existed in the natural
extracts. The results in Fig. 4 showed that propolis 2 and 6
had the activities to suppress the IκB–EGFP degradation,
but another propolis did not cause the increase in EGFP
fluorescence.
3.3 HQ Inhibits the Degradation of IκB by Lowering
the Phosphorylation of IκB Protein
293 Cells were treated with different dosages of HQ, and
the intracellular IκB proteins were detected with dot
immunoblotting method. The results revealed that as the
concentration of HQ was increased from 5 μM to 100 μM,
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Fig. 3 HQ antagonizes the effect of TNF-α-induced NF-κB produc-
tion in pIκB–EGFP-transfected 293 cells. Transfected 293 cells were
added either with TNF-α (100 μM) or TNF-α plus HQ (100 μM).
After 24-h incubation, the amount of IκB–EGFP proteins (shown as
fluorescence intensity) was measured by flow cytometry (results
expressed as mean ± standard deviation)
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Fig. 2 Fluorescence intensity induced by HQ-treated pIκB–EGFP-
transfected Huh 7 cells. Mock- or pIκB–EGFP-transfected Huh 7 cells
were treated with 20 and 100 μM HQ. After 24-h incubation, the
amount of IκB–EGFP proteins (shown as fluorescence intensity) was
measured by flow cytometry (results expressed as mean ± standard
deviation)
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Fig. 1 The accumulation of IκB–EGFP proteins in pIκB–EGFP-
transfected Huh7 cells caused by microbial metabolite-derived
antioxidant. a The representative histogram pattern of pIκB–EGFP-
transfected cell with or without antioxidant treatment. b Antioxidants
including HQ, PA, β-PPA, and HA (100 μM) were added into pIκB–
EGFP-transfected Huh 7 cells. Growth medium was also added into
another well as control. After 24-h incubation of the antioxidants, the
amount of IκB–EGFP proteins (shown as fluorescence intensity) was
measured by flow cytometry (results expressed as mean ± standard
deviation)
134 Lin et al.the amounts of IκB protein also increased in cells (Fig. 5a).
The phosphorylation of IκB was also determined by anti-
phosphorylation IκB antibody. The results showed that HQ
could affect the phosphorylation of IκB protein. As the
concentrations of HQ were increased, the amounts of
phosphorylated IκB protein were decreased. An increase
in HQ dosage could inhibit the phosphorylation of IκB
protein (Fig. 5b).
3.4 Temporary Contact of Low Dosage HQ can Inhibit
the Cell Adhesion Ability without Cell Lethality
293 Cells (2.5×10
5) were exposed to 10 μM HQ. Time-
dependent detachment of 293 cells was observed during the
short-term contact of HQ (0–4 h) (Fig. 6a–e). After HQ
exposure, harvesting detached cells and seeding them again
found that removing HQ from 293 cells can regain their
adhesive ability (Fig. 6f).
3.5 In Vitro Tumor Cytotoxicity by Long-Term
and High-Dose Treatment of HQ
The tumor cytotoxicity induced by HQ was accessed via
the cell death rate of COLO320, K-Balb, Hep3B, and Daudi
tumor cell lines. A dose-dependent death was observed in all
fourcelllines.Also,200μM HQ causedalmostall COLO320
cells to die, and the IC50 was 88.3 μM( F i g .7a). In K-Balb
cells, the decrease in cell number was due to increasing
concentration of HQ (0–50 μM), and the IC50 was 3.1 μM
(Fig. 7b). The same situation was observed in the Hep3B
cells; 50 μM HQ caused large amounts of cells to detach and
die (IC50=34 μM) (Fig. 7c). In Daudi cells, 0–200 μMo f
HQ also caused a slow increase in cell death, and IC50 was
104.8 μM( F i g .7d).
4 Discussion
Because of rapid degradation of IκB with stimulation, it
could be a target to analyze the effect of drugs on the
NF–κB signaling pathway [8]. Activation of the NF-κB can
be detected by green fluorescent protein-tagged IκB
degradation in living cells [9]. In this study, we first used
the IκB–EGFP protein as an indicator to screen microbial
metabolites and demonstrated that the effective substance
selected from the screening system can inhibit activity of
NF-κB by inhibition of IκB degradation. Mechanisms for
regulation of NF-κB activity comprise inhibiting the
activation of IKK complex, inhibiting the phosphorylation
of IκB, preventing the degradation of IκB, blocking the
migration of NF-κB to nucleus, and decreasing the DNA
binding activity of NF-κB. For activation of NF-κB, IκB
must be phosphorylated to release itself from the complex
of NF-κB and process of degradation. In this study, the
results revealed that the degradation of IκB is exactly a
good reference to relate the activity of NF-κB. Thus,
utilization of IκB degradation as an indicator to judge
intracellular NF-κB activity can be established as a drug
screen system for selecting microbial metabolites.
The degradation of endogenous IκB regulates NF-κB
activation, and IκB can be degraded rapidly within 2 h to
prevent the accumulation of IκB. Thus, the stability of
cellular IκB is low. In this system, we find that the changes
in the amounts of IκB or phosphorylated IκB are similar to
endogenous IκBo rI κB–EGFP, which is dependent on the
stimulation with the NF-κB activator, such as TNF-α or
PMA. In addition, the half-life of IκB is greatly shortened
to 5–30 min with TNFα-induced IκB degradation. There-
fore, we proposed that the endogenous IκB could not
influence the expression of IκB–EGFP.
Plasmid pIκB–EGFP was transfected into different cell
lines (Huh 7 and 293 cells) to establish cell-based drug
HQ (μ μM) 0 5 20 100
IκB
pIκB
β-actin
Fig. 5 The mechanism used by HQ prevents the degradation of IκB
proteins. The amount of intracellular unphosphorylated and phosphor-
ylated IκB proteins of 5–100 μM HQ-treated 293 cells was detected
by Western blot. The quantity of IκB and phosphorylated IκB proteins
was induced by different dosages of HQ
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Fig. 4 The screening effect of IκB–EGFP drug discovery system
assayed on propolis. Taiwan propolis (propolis 1 and 2), Brazil red
propolis (propolis 3 and 4), and Brazil green propolis (propolis 5 and 6)
were dissolved in 80% ethanol and used as test samples to verify the
ability of the pIκB–EGFP drug discovery system. pIκB–EGFP-trans-
fected 293 cells were used as a control group; PMA (50 ng/ml) and
curcumin were other control groups used for initiating or inhibiting IκB–
EGFP degradation. Ethanol (80%) was added into pIκB–EGFP-trans-
fected 293 cells to verify if the fluorescence increase was due to the
background effect of solvent used. After 24-h incubation of the propolis,
the amount of IκB–EGFP proteins (shown as EGFP expression fold
compared to control group) was measured by flow cytometry (results
expressed as mean ± standard deviation)
Microbial Metabolites with NF-κB Inhibitor Activity 135screening system, and the results showed that the pIκB–
EGFP-transfected 293 cells have better response in fluo-
rescent expression after HQ treatment than Huh7 cell
(Figs. 2 and 3). Therefore, the sensitivity of IκB
degradation-based drug screening system is related to cell
type. The cells that have stronger intracellular NF-κB
activity may be more proper to develop the screening
system.
The most common active form of NF-κB is p50/p65
heterodimer, whereas c-Rel, Rel-B, or p52 also has the
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Fig. 7 In vitro tumor cytotoxicity induced by high dosage of HQ. One
hundred microliters of cells suspended in complete medium at a
concentration of 2×10
4 cells/ml was seeded in a 96-well plate
overnight and treated with different concentrations of HQ. After 24-
h incubation, HQ cytotoxicity was determined by MTS assay. a
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Fig. 6 Cell adhesion ability affected by low dosage of HQ. 293 Cells
were seeded in a six-well plate and incubated with 10 μM HQ. a–e
The cell detachment patterns were observed at 0, 0.5, 1, 2, and 4 h. f
After this 4-h observation, HQ from 293 cells was removed and seeded
again to test the adhesion ability
136 Lin et al.ability to form a heterodimer with p50. Except for
heterodimers, the homodimers of NF-κB including p50/
p50, p52/p52, and RelA/RelA also existed and have
activities in cells. These NF-κB dimers have different
affinities to NF-κB binding sequence in promoter [10]. In
addition, the expressions of identical gene are regulated
with different NF-κB dimers in different cells. For example,
the vascular cell adhesion molecule-1 (VCAM-1) gene of
endothelial cells is regulated by p50/p65; however, the
VCAM-1 gene of Hela cell is regulated by p65/p65 but not
p50/p65 [11]. It can be concluded that the members of IκB
family—IκB-α,I κB-β,I κB-γ, and Bcl-3 proteins—all
have the ability to suppress NF-κB translocation into cell
nucleus. Whereas different IκB have their own specific
target molecules, such as IκB-α that prefers binding to p50/
p65 and p65/p65, nevertheless it inefficiently binds to p50/
p50 [12]. In addition, IκB-β specifically binds to p65 and
c-Rel but not p50, and IκB-γ and Bcl-3 specifically bind to
p50 [13]. Thus, different cells have various NF-κB
existences and regulate the activity of NF-κB by different
IκB members. Because of the widespread importance of
NF-κB, it has been difficult to develop NF-κB inhibitors
that act specifically in a specific cell to employ in therapy
of diseases. Therefore, certain specific IκB inhibitors may
be found according to our model presented here and inhibit
specific NF-κB activity in certain cells without affecting the
NF-κB signal pathway in other cells.
HQ was chosen from this system, and the previous
literatures showed that it could decrease the secretion of
cytokines [14, 15]. HQ exists in extract of tobacco and
inhibits human lymphocytes to produce IL-1β, IL-2, and
TNF-α [16]. HQ has also been reported to reduce the
expression of CD19 by decreasing the intracellular activity
of NF-κB, and its mechanism is not due to the inhibition of
the DNA binding activity of NF-κB[ 17]. In this study, we
first reveal that HQ inhibits the activity of NF-κBb y
inhibiting the degradation of IκB.
In this study, we have demonstrated that the plasmid
pIκB–EGFP transfectants (Huh 7 and 293 cells) were used
as a drug screening system to seek NF-κB inhibitor, and we
did obtain HQ of microbial origin, which have been shown
to have a significant activity against NF-κB activity, from
the screening program. NF-κB target genes have been
studied and are involved in immunity, inflammation, cell
proliferation, apoptosis, and cell migration [18]. A close
connection between inflammation and cancer has also been
suspected. NF-κB pathway is also involved in cell
adhesion. The cell adhesion molecule, such as integrin,
has been correlated with the cell differentiation or adhesion.
HQ, a NF-κB inhibitor, can block upstream signaling for
both NF-κB activation and cell adhesion. HQ also inhibits
NF-κB activation through suppressing integrin expression
for cell adhesion [19]. HQ exposure affected cell prolifer-
ation and delayed cell growth and attachment in a dose-
dependent manner [19]. In addition, HQ diminishes surface
levels of CD29 and CD18 and suppresses CD29-mediated
cell–cell adhesion in monocyte [20]. Therefore, such
downregulation with HQ treatment may be an inhibitory
mechanism for cell adhesion. Therefore, the system may
provide a good method to develop a new drug for
inflammation and cancer therapy (Fig. 7).
Propolis was used to determine whether this screening
system is sensitive enough to identify the effective
substance from a natural extracted mixture. The results
showed that propolis increased the fluorescence of pIκB–
EGFP-transfected cells compared to negative control
groups. Different kinds of propolis were extracted by 80%
ethanol, and the results showed that the effective substance
for inhibiting the IκB degradation is favorable in ethanol
(Fig. 4). The previous evidences revealed that the effective
substance should be caffeic acid phenethyl ester which is
hydrophobic and can inhibit NF-κB activity [21]. In
addition, red propolis or green propolis was harvested
respectively in winter or summer, and the results also
showed different propolises harvested in different seasons
have different activities to inhibit the IκB degradation
(Fig. 4). Propolis is the product after bees harvested the
resin from the tree, and different seasons would affect
what kind of tree resin was harvested by the bee. Thus,
the propolises have different activities to IκB degradation
that is reasonable. This study showed that this assay
could determine the activity of natural product for IκB
degradation.
In this study, an assay was established to monitor the
activities of substances for IκB degradation in the cell. The
results showed that the assay could be applied to pure
chemical and natural mixture. After selection by this assay,
the chosen candidate exactly has the ability to cause the
change in the NF-κB activity via regulating the IκBa n d
further regulatethe expressionrelatedwithNF-κB. Therefore,
the systemmay provide a good methodto develop a new drug
for certain diseases that are related to NF-κB activities such as
inflammation and cancer.
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